EGFR and lung adenocarcinoma: EMT may underlie phenotypic changes in EGFR-mutated lung adenocarcinomas treated with TKIs, although this has mostly been demonstrated in in vitro or cell-line studies [81,176] and, rarely, in clinical settings, based mostly on case series or case reports [147,157,158,160,165].